Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ThermaGenix is a private life science tools company focused on improving PCR and RT-PCR performance through proprietary reaction additives rather than developing therapeutic drugs. Its core products, including ThermaStop, ThermaGo, and ThermaStop-RT, are designed to improve polymerase or reverse transcriptase specificity and fidelity, reduce non-specific amplification, and increase yield for downstream applications such as genotyping, sequencing sample preparation, diagnostics, and multiplex PCR. The company was founded by Brandeis University professor Lawrence Wangh and has licensed underlying intellectual property from Brandeis. ThermaGenix appears to operate as an active commercial reagent supplier serving research and assay-development workflows in molecular biology and diagnostics. The business is best characterized as a life science tools/platform company rather than a clinical-stage biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ThermaGenix.